The Eighth Edition Lung Cancer Stage Classification

2016/10/22 by Frank C. Detterbeck, Daniel J. Boffa, Anthony W. Kim +2 · 30 citations
Medicine · #Lung Cancer Diagnosis and Treatment #Lung Cancer Treatments and Mutations #Radiomics and Machine Learning in Medical Imaging

paper · doi:10.1016/j.chest.2016.10.010

Cited by

• Assessing the robustness of heterogeneous treatment effects in survival analysis under informative censoring
• Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay
• Spot On
• Lung MRI: Indications, Capabilities, and Techniques— AJR Expert Panel Narrative Review
• Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
• Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. [europepmc]
• Impact of a Bayesian penalized likelihood reconstruction algorithm on image quality in novel digital PET/CT: clinical implications for the assessment of lung tumors. [europepmc]
• Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. [europepmc]
• Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. [europepmc]
• Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study. [europepmc]
• The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. [europepmc]
• MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. [europepmc]
• The efficiency of 18 F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. [europepmc]
• Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma. [europepmc]
• Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules. [europepmc]
• 18 F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival. [europepmc]
• Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer. [europepmc]
• B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors. [europepmc]
• Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. [europepmc]
• The current treatment landscape in the UK for stage III NSCLC. [europepmc]
• Universal scaling laws rule explosive growth in human cancers. [europepmc]
• Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. [europepmc]
• Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. [europepmc]
• Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. [europepmc]
• USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. [europepmc]
• Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. [europepmc]
• PM2.5 promotes NSCLC carcinogenesis through translationally and transcriptionally activating DLAT-mediated glycolysis reprograming. [europepmc]
• Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. [europepmc]
• Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. [europepmc]
• An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. [europepmc]